Navigation Links
EntreMed Commences Continuous Dosing Clinical Trial For MKC-1
Date:4/2/2008

Phase 1 Study to be Conducted in Advanced Cancer Patients

ROCKVILLE, Md., April 2, 2008 /PRNewswire-FirstCall/ -- EntreMed, Inc. (Nasdaq: ENMD), a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and inflammatory diseases, today announced that it has commenced a Phase 1, open-label, continuous dosing study with its oral cell cycle inhibitor, MKC-1, in patients with advanced or metastatic solid tumors. The clinical trial will be conducted at the University of Wisconsin, Paul P. Carbone Comprehensive Cancer Center. Dr. Glenn Liu, Assistant Professor of Medicine, University of Wisconsin, will serve as principal investigator.

(Logo: http://www.newscom.com/cgi-bin/prnh/20010620/ENMDLOGO )

The purpose of the dose-escalation trial is to determine the maximum tolerated dose (MTD) of MKC-1 administered orally twice a day continuously in advanced or refractory solid tumor patients. Response and/or tumor marker improvement will also be evaluated. Up to 24 patients with metastatic or unresectable solid tumors for which standard curative measures do not exist or are no longer effective will be enrolled.

MKC-1 is a novel, orally-active cell cycle inhibitor with in vitro and in vivo efficacy against a broad range of human solid tumor cell lines, including multi-drug resistant cell lines. Data from previous studies with MKC-1 demonstrate broad-acting antitumor effects, showing tumor growth inhibition or regression in multiple preclinical models, including paclitaxel-resistant models. To date, MKC-1 has been evaluated in over 400 patients in multiple Phase 1 and 2 clinical trials.

MKC-1 has been
'/>"/>

SOURCE EntreMed, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. EntreMed Commences Phase 2 Study With MKC-1 in Ovarian/Endometrial Cancers
2. EntreMed to Present at The New York Society of Security Analysts Industry Conference
3. EntreMed Commences Phase 2 Study with MKC-1 in Pancreatic Cancer
4. EntreMed Shows Increased Survival With MKC-1 in Preclinical Renal Cell Cancer Model
5. EntreMed Reports Phase 1 PK and Preclinical Efficacy Results for ENMD-1198
6. EntreMed Raises $20 Million to Support Clinical Development Program
7. EntreMed Presents Data for Phase 2 Study of MKC-1 in Metastatic Breast Cancer
8. Anesiva Commences Phase 3 Clinical Trial of Adlea(TM) for Reducing Post-Surgical Pain Following Bunionectomy
9. BioNumerik Commences Global Phase III Ovarian Cancer Trial on Novel Anticancer Drug Candidate Known as Karenitecin(R)
10. Nektar Commences Phase 2 Trial of NKTR-118 (oral PEG-naloxol) Evaluating Efficacy and Safety as Treatment for Opioid-Induced Bowel Dysfunction
11. Nektar Commences Phase 2 Clinical Development Program for NKTR-102 (PEG-Irinotecan) in Colorectal Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2014)... Maine , Dec. 22, 2014  Mark ... analysis brief providing a summary of the 2015 ... plan enrollment trends.  According to ... for Planning and Evaluation, Department of Health and ... were enrolled in individual medical plans through the ...
(Date:12/22/2014)... TAIPEI , Dec. 22, 2014 ... received Notice of Allowance for AC-201, TWi Biotechnology,s ... Office in China for ... or its pharmaceutically acceptable salts, active metabolite for ... covers the methods of treatment using AC-201 for ...
(Date:12/19/2014)... , Dec. 19, 2014 You,re visiting the ... and cleaning when he or she says you need ... heard before, you may have several questions and feel ... relieved to know it,s nothing to worry about. The ... questions and alleviate any anxiety the public may have ...
Breaking Medicine Technology:Insights into the Marketplace and Individual Market Growth 2TWi Biotechnology Receives Notice of Patent Allowance for Its Lead Drug Candidate AC-201 for the Indication of Type II Diabetes in China 2TWi Biotechnology Receives Notice of Patent Allowance for Its Lead Drug Candidate AC-201 for the Indication of Type II Diabetes in China 3Root Canals Have Become More Routine 2
... pharmaceutical products - particularly those that are first-in-class, socially ... not only external disease state communication but also internal ... a product for a new or relatively unknown condition ... the new disease before introducing a new product to ...
... Company (NYSE: LLY ) today announced that the ... a prior ruling by the U.S. District Court for the ... the company,s method-of-use patent on Strattera® (atomoxetine). In the case ... et al, the court ruled in favor of Lilly, ...
Cached Medicine Technology:Building Support for a New Product Through Effective Internal Disease State Communication 2U.S. Court of Appeals Affirms Validity of Lilly's Strattera Patent 2
(Date:12/22/2014)... Pasadena sleep apnea dentist, ... apnea. Drowsy drivers are 15 times more likely to ... and some experts believe that sleep-deprived drivers may be ... Unfortunately, millions of Americans may be sleep-deprived without even ... Medicine, about 18 million Americans have sleep apnea, but ...
(Date:12/22/2014)... Luxury Linen purveyor Peacock Alley once again joined ... logistics and support for one of Dallas’ largest holiday toy ... of giving back to the community in which it lives ... were Whataburger® and 99.5 The Wolf. , There is no ... to children who would otherwise not receive any is a ...
(Date:12/22/2014)... Ill. (PRWEB) December 21, 2014 ... recommendations for chest computed tomography (CT) to evaluate ... relevant findings, including cancer, according to a new ... , Researchers said the findings show that radiologist ... represent valuable contributions to patient care. , RAIs, ...
(Date:12/21/2014)... (PRWEB) December 22, 2014 In ... is segmented by power source, product, and application. ... electric-powered, battery-powered, and pneumatic instruments. By product, the ... and accessories segments. The handpieces market is further ... devices, suction coagulators, laparoscopic instruments, shavers, wire/pin drivers, ...
(Date:12/21/2014)... Beverly Hills, Ca (PRWEB) December 21, 2014 ... Dr. Khanna was a guest at the Aspen Helicopters ... for kids and a Santa with sleigh, flown by ... the helicopter appeared invisible; only Santa with sleigh was ... both during day and night. Dr.Khanna has helped many ...
Breaking Medicine News(10 mins):Health News:Pasadena Dentist, Dr. Marine Martirosyan, Now Offers Consultations for Sleep Apnea 2Health News:Peacock Alley and Community Partners of Dallas Fulfill an Estimated 12,000 Holiday Wishes for Deserving Children 2Health News:RSNA: Radiologist Recommendations for Chest CT Have High Clinical Yield 2Health News:RSNA: Radiologist Recommendations for Chest CT Have High Clinical Yield 3Health News:Global Powered Surgical Instruments Market Hit to $2.1 billion by 2019 - New Research Report by MarketsandMarkets 2Health News:Global Powered Surgical Instruments Market Hit to $2.1 billion by 2019 - New Research Report by MarketsandMarkets 3Health News:Global Powered Surgical Instruments Market Hit to $2.1 billion by 2019 - New Research Report by MarketsandMarkets 4
... Faced with a barrage of pressing issues, the ... agenda. The timing bodes well for change, according ... University Center for Health Policy and Professionalism, associate professor ... a pediatrician at Riley Hospital for Children. , "If ...
... Feb. 6 Turner Construction Company, the nation,s leading ... Northern Inyo Hospital to proceed with the $42 million ... for Phase Two will start in March 2009 with ... of a new central plant, emergency rooms, ICU, CCU, ...
... Colo., Feb. 6 Baxa Corporation, an Englewood Colorado-based medical ... of the Top 50 Family-Owned Companies in Colorado. Qualifying ... be controlled by a single family, and controlling family members ... has to have been involved in the company for at ...
... Medical Group Inc.,(OTC Bulletin Board: WMDG; "Winner Medical"), ... and wound care products) in China, today,announced that ... first quarter,ended December 31, 2008 on Friday, February ... The earnings release will be available on the ...
... (Nasdaq: EVVV ) will release its 2008 fourth ... 2009 on Tuesday, Febuary 24, 2009, before regular market trading ... same day at 7:30 a.m. Central Time (8:30 a.m. Eastern ... full-year operating results and future outlook, followed by a question ...
... ... Brookfield, Wisconsin (PRWEB) February 6, 2009 -- Watching your weight? ... International Foundation of Employee Benefits Plans found that of those ... loss program., , ,When asked their primary reason for offering a ...
Cached Medicine News:Health News:Prioritizing health-care reform components 2Health News:Turner to Manage Construction of $42 Million Expansion of Northern Inyo Hospital in Bishop, Calif. 2Health News:Baxa Corporation Ranks Seventh in ColoradoBiz Magazine's Top 50 Family-Owned Companies 2Health News:Baxa Corporation Ranks Seventh in ColoradoBiz Magazine's Top 50 Family-Owned Companies 3Health News:Winner Medical Schedules 2008/2009 First Quarter Earnings Release on Friday, February 13, 2009 2Health News:ev3 Inc. to Report 2008 Fourth Quarter and Full-Year Financial Results and Host Conference Call on February 24, 2009 2Health News:Employee Weight Loss Programs Offered By Half of Employers Who Provide Wellness Programs 2Health News:Employee Weight Loss Programs Offered By Half of Employers Who Provide Wellness Programs 3
... The AFX Lens is ... for use in an air-filled ... use as a primary air-fluid ... profile and sutureless design make ...
... 45° Prism is designed ... and are recommended for ... BRVO etc.) and Rhegmatogenus ... be used for panretinal ...
... Chalam Flat is designed for ... and induction of posterior vitreous ... for macula whole surgery, epiretinal ... tractional epiretinal membranes. Direct image ...
... magnification and increased stereopsis, the Central Retinal ... to the equatorial regions. The Central Retinal ... in membrane peeling in proliferative vitreoretinopathy extending ... The ACS Vitrectomy Lenses from Volk can ...
Medicine Products: